Posted by Michael Wonder on 10 Nov 2023
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
10 November 2023 - CHMP positive opinion in the European Economic Area for first biosimilar to Stelara, a biologic therapy within gastro-enterology, dermatology and rheumatology.
Partners STADA and Alvotech today announced that the CHMP within the EMA has adopted a positive opinion for Uzpruvo (AVT04), a biosimilar candidate to Stelara (ustekinumab).
